Erratum to “Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study”

IF 6.1 2区医学 Q1 ONCOLOGY

Cancer Pub Date : 2025-03-05 DOI:10.1002/cncr.35803

引用次数: 0

Abstract

This erratum corrects the following:

Luskin MR, Yin J, Lozanski G, et al. Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study. Cancer. 2025;131(4):e35750. doi:10.1002/cncr.35750

The article ’s title was originally published in truncated fashion (“Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study”). The revised full title appears below and should read: “Incorporation of Alemtuzumab into Frontline Therapy of Adult Acute Lymphoblastic Leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.” The full title as listed above is correct.

We apologize for this error.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer 医学-肿瘤学

CiteScore

13.10

自引率

3.20%

发文量

480

审稿时长

2-3 weeks

期刊介绍： The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research